Drugs / Dabigatran etexilate
Dabigatran etexilate
also known as
BIBR 1048 MS · BIBR 1048 · dabigatran · Pradaxa · Dabigatran Etexilate 110 mg (Pradax) · Dabigatran Etexilate Mesylate
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | PRADAXA | — | 2014-04-04 – 2021-06-21 | fda.gov ↗ |
| Approved | US (FDA) | PRADAXA | — | 2010-10-19 | fda.gov ↗ |
| Approved | EU (EMA) | Pradaxa | — | 2008-03-17 | europa.eu ↗ |
Trials 113 · started per year
today
EU approved 2008
US approved 2010
1
3
2
4
6
2
5
5
6
2
5
6
3
5
5
4
5
3
4
7
5
1
2
1
8
4
6
2
1
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04459585 | Aug → Oct 2020 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 168 trials | ||||||
| Phase 1 | NCT07515339 | Apr → Jun 2026 | chronic kidney disease | Bayer | Withdrawn | No outcome recorded |
| Phase 1 | NCT07190430 | Oct → Dec 2025 overdue | atopic eczema | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06791187 | Jan → Feb 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06693518 | Nov 2024 → Jan 2025 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06504862 | Aug → Oct 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06533280 | Aug 2024 | HIV infectious disease | ViiV Healthcare | Withdrawn | No outcome recorded |
| Phase 1 | NCT06329895 | Mar → Jun 2024 | non-small cell lung carcinoma | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT05959447 | Jul → Oct 2023 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT05788328 | Mar → Sep 2023 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05673889 | Jan → Mar 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05480475 | Sep 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05471817 | Aug → Sep 2022 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT05438303 | Jun → Dec 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05347979 | May → Jul 2022 | Cushing syndrome, neoplasm | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05492318 | Mar → May 2022 | — | Italfarmaco | Completed | No outcome recorded |
| Phase 1 | NCT05368805 | Mar → Apr 2022 | colorectal cancer | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT04749914 | Feb → Jul 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04257032 | Feb → Sep 2020 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04208061 | Dec 2019 → Mar 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03728101 | Nov → Dec 2018 | — | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03492437 | May → Aug 2018 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT03311841 | Mar → Aug 2018 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03237416 | Aug → Oct 2017 | prostate neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03143166 | May → Jul 2017 | NAFLD1 | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03086356 | May → Sep 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02945020 | Nov 2016 → Jan 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02426229 | Feb 2016 → Jun 2018 | interstitial lung disease, scleroderma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT02568397 | Oct 2015 → Jan 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02044367 | Jan → Apr 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01734772 | Nov 2012 → Jun 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01711853 | Oct 2012 → Dec 2013 | chronic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01590823 | Jul → Sep 2012 | blood coagulation disease | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 1 | NCT01595854 | May → Jun 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01379300 | May → Dec 2011 | thrombotic disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01306162 | Feb → May 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01241539 | Nov 2010 → May 2011 | cardiovascular disorder, chronic renal failure syndrome | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171572 | Oct → Nov 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02173717 | Jun → Jul 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170675 | Jun → Jul 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171611 | Mar → May 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171624 | Mar → Apr 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171559 | Aug → Sep 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171585 | Jun → Aug 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171546 | Nov 2007 → Jan 2008 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02171052 | Jun → Aug 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171507 | May → Jul 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171026 | Apr → Jun 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170987 | Mar → May 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171455 | Jan 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170571 | Jul → Dec 2005 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171000 | Apr → May 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02182024 | Apr 2005 → Mar 2006 | impaired renal function disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170909 | Dec 2004 → Jun 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170844 | Jun → Aug 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170597 | Aug → Sep 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02173730 | Nov 2002 → Feb 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170610 | Mar → May 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170623 | Feb → Apr 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170636 | Jan → Mar 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170896 | Oct → Dec 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170805 | Apr → Jun 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170792 | Feb → Mar 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170584 | Jan → Mar 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170766 | Oct → Dec 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170740 | Nov 1999 → Jan 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170922 | Jul → Aug 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170831 | May → Jul 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170116 | Nov → Dec 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT02256683 | Jul 2014 → May 2018 | atrial fibrillation | Johannes Gutenberg University Mainz | Terminated | No outcome recorded |
| Phase 2 | NCT01773174 | Jan 2013 → Dec 2015 | venous thromboembolism | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 2 | NCT01505881 | Dec 2011 → Jun 2013 | cardiac valvular defect, thrombotic disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT01452347 | Oct 2011 → Jun 2013 | heart valve disorder | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT01083732 | Mar 2010 → Feb 2016 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00844415 | Jun 2009 → Feb 2012 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00621855 | Mar 2008 → Oct 2009 | coronary artery disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01136408 | Nov 2005 → Sep 2006 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00246025 | Oct 2005 → Jun 2007 | osteoarthritis, knee, venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00157248 | Dec 2003 → Jan 2009 | atrial fibrillation, stroke disorder | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT01225822 | Nov 2002 → Aug 2003 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02170935 | Apr → Jun 2002 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02170701 | Oct 2000 → Jun 2001 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT03217448 | Oct 2017 → Jan 2019 | cerebral sinovenous thrombosis | Capital Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03240120 | Sep 2017 → May 2021 | pulmonary embolism, venous thromboembolism | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT02913326 | Dec 2016 → Jun 2018 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02239120 | Nov 2014 → Aug 2018 | ischemic stroke | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02197416 | Sep 2014 → Oct 2019 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02164864 | Jul 2014 → Jun 2017 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01895777 | Sep 2013 → Oct 2019 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00680186 | Apr 2008 → May 2011 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00657150 | Mar 2008 → Sep 2009 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00558259 | Nov 2007 → Feb 2011 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00291330 | Feb 2006 → May 2009 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00168818 | Nov 2004 → Jul 2006 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00152971 | Nov 2004 → Jun 2006 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00168805 | Nov 2004 → May 2006 | osteoarthritis, knee, thrombotic disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT05735639 | Jan 2024 → Jun 2027 expected | varicose disease, venous thromboembolism | Imperial College London | Recruiting | No outcome recorded |
| Phase 4 | NCT06273215 | Mar 2023 → Dec 2025 | diabetes mellitus | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05747768 | Jul 2022 → Jun 2024 | chronic kidney disease | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03789695 | Nov 2018 → Jul 2021 | atrial fibrillation, chronic kidney disease, type 2 diabetes mellitus | Irina Ermolaeva | Unknown | No outcome recorded |
| Phase 4 | NCT03539055 | Sep 2018 → Dec 2023 | atrial fibrillation, thrombotic disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03975062 | Dec 2017 → Dec 2020 | atrial fibrillation | Ural State Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03061006 | Mar 2017 → Mar 2021 | brain ischemia, dementia | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02979561 | Oct 2016 → Jun 2018 | — | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 4 | NCT02591225 | Oct 2015 → Dec 2017 | atrial fibrillation | University of Ulm | Unknown | No outcome recorded |
| Phase 4 | NCT02348723 | Apr 2015 → Nov 2016 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT01976507 | Oct 2013 → Dec 2016 | atrial fibrillation, atrial flutter | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01896297 | Jul 2013 → Oct 2015 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT01546883 | Feb 2012 → Dec 2013 | atrial fibrillation | University of Utah | Terminated | No outcome recorded |
| Phase 4 | NCT01184989 | Aug 2010 → Apr 2013 | arthropathy, erosive, venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06360055 | Apr → Nov 2024 | — | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT05715658 | Aug 2022 → Jun 2023 | atrial fibrillation | Dongyang Liu | Unknown | No outcome recorded |
| — | NCT01593150 | Nov 2011 → Feb 2015 | atrial fibrillation | Odense University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07629999 Background | Jun 2026 → Jun 2027 expected | — | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03807856 Comparator | Jun 2019 → Jul 2020 | acute pancreatitis | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT03495739 Comparator | Feb → Jun 2018 | — | Huons Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02710630 Comparator | Mar → May 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02170974 Comparator | Jul → Aug 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02171442 Comparator | Apr → May 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01627665 Comparator | Oct 2011 → Jun 2014 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06551402 Comparator | Aug 2024 → Oct 2026 expected | cerebral sinovenous thrombosis | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06551415 Comparator | Aug 2021 → Sep 2024 overdue | cerebral sinovenous thrombosis | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT01924065 Comparator | Aug 2013 → Aug 2017 | atrial fibrillation, stroke disorder | Suleyman Demirel University | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT03129555 Comparator | Apr 2023 → Mar 2027 expected | pulmonary embolism, venous thromboembolism | Herlev and Gentofte Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03129490 Comparator | Apr 2023 → Oct 2027 expected | atrial fibrillation, atrial flutter | Herlev and Gentofte Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04695106 Background | Oct 2021 → Jul 2026 overdue | acute coronary syndrome, atrial fibrillation | Medical University of Gdansk | Recruiting | No outcome recorded |
| Phase 4 | NCT03183843 Comparator | Jun 2016 → Jun 2018 | atrial fibrillation, heart valve disorder | Research Institute for Complex Problems of Cardiovascular Diseases, Russia | Unknown | No outcome recorded |
| Phase 4 | NCT02646267 Comparator | Mar 2016 → Jan 2018 | atrial fibrillation | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02666157 Comparator | Jan 2016 → Dec 2018 | atrial fibrillation | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01493557 Comparator | Dec 2011 → Jul 2014 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00559988 Background | Feb 2008 → Jun 2013 | arterial occlusion, atrial fibrillation, atrial flutter, stroke disorder | Biotronik, Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 137 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dabigatran etexilate | “The primary objective of this trial is to investigate the relative bioavailability of five different tablet formulations of Dabigatran Etexilate, Formulation A1, Formulation...” NCT02710630 ↗108“Dabigatran etexilate (DE) is an anticoagulant with proven efficacy and tolerability for stroke prevention in patients with non-valvular atrial fibrillation.” PMID 31667735 ↗ Jun 2020 “Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.” NCT06533280 ↗ “375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail” NCT03311841 ↗ “Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement” NCT00152971 ↗ “OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA” NCT00559988 ↗ “Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban” NCT01627665 ↗ “warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage” NCT01924065 ↗ “Dabigatran Etexilate 150 mg” NCT06693518 ↗ “Drug: Dabigatran Etexilate” NCT04695106 ↗ |
| Known as | BIBR 1048 | “A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin” NCT01136408 ↗ |
| Known as | BIBR 1048 MS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02170922 ↗ |
| Known as | dabigatran | “This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients...” PMID 21225098 ↗ Jan 20117“BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation.” PMID 23991661 ↗ Aug 2013 “Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.” PMID 23425163 ↗ Feb 2013 “Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism.” PMID 33290737 ↗ Dec 2020 “introduction of Pradaxa (Dabigatran) has enabled an earlier DC cardioversion, reducing time to cardioversion to a 3 week period.” NCT01593150 ↗ “Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio)” NCT02239120 ↗ “Dabigatran is a drug used in the treatment of blood clots in a vein” NCT06329895 ↗ “100 CVT patients will receive dabigatran 150mg Bid for 6 months.” NCT06551415 ↗ |
| Known as | Dabigatran Etexilate 110 mg (Pradax) | “Dabigatran Etexilate 110 mg (Pradax)” NCT01590823 ↗ |
| Known as | Dabigatran Etexilate Mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03807856 ↗ |
| Known as | Pradaxa | “To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with...” NCT01184989 ↗4“Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis” NCT01241539 ↗ “Pradaxa (dabigatran etexilate)” NCT01493557 ↗ “Pradaxa, dabigatran etexilate” NCT01896297 ↗ |
| Action | Inhibit | “Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.” PMID 17869635 ↗ Sep 2007 |
| Route | Oral | “Dabigatran Etexilate Administered Orally (Capsules)” NCT00152971 ↗ |